BMRN Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 1.85%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $17,856,129.12

BioMarin Pharmaceutical Insider Trading History Chart

BioMarin Pharmaceutical Share Price & Price History

^$64.26

▲ +0.81 (1.28%)

As of 11/22/2024 01:00 AM ET

Days: 30 | 90 | 365

I was wrong. Dead wrong.

From Porter & Company | Ad

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Here’s the full story for you.

BioMarin Pharmaceutical Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/12/2024	Charles Greg Guyer	EVP	Sell	5,278	$66.37	$350,300.86	68,909
5/30/2024	Brian R. Mueller	CFO	Sell	5,000	$75.19	$375,950.00	72,159
5/28/2024	George Eric Davis	EVP	Sell	40,850	$74.51	$3,043,733.50	56,157
5/9/2024	Jean Jacques Bienaime	Director	Sell	20,000	$81.62	$1,632,400.00	474,994
5/2/2024	George Eric Davis	EVP	Sell	1,850	$85.01	$157,268.50	56,157
4/12/2024	Jean Jacques Bienaime	Director	Sell	20,000	$91.26	$1,825,200.00	474,994
4/10/2024	Erin Burkhart	CAO	Sell	2,286	$90.00	$205,740.00	16,156
3/28/2024	George Eric Davis	EVP	Sell	24,602	$88.34	$2,173,340.68	55,856
3/5/2024	Henry J. Fuchs	Insider	Sell	35,341	$85.18	$3,010,346.38	212,117
3/5/2024	Jean Jacques Bienaime	Director	Sell	1,000	$85.51	$85,510.00	561,203
3/5/2024	Jeffrey Robert Ajer	EVP	Sell	4,000	$87.07	$348,280.00	94,047
2/27/2024	Jean Jacques Bienaime	Director	Sell	1,000	$90.35	$90,350.00	562,203
2/9/2024	Jean Jacques Bienaime	Director	Sell	15,000	$88.28	$1,324,200.00	419,602
1/9/2024	Jean Jacques Bienaime	Director	Sell	10,000	$98.19	$981,900.00	425,162
12/21/2023	Jean Jacques Bienaime	Director	Sell	10,000	$93.99	$939,900.00	425,112
12/13/2023	George Eric Davis	EVP	Sell	13,764	$95.30	$1,311,709.20	55,710
8/16/2023	Jeffrey Robert Ajer	EVP	Sell	5,000	$90.00	$450,000.00	60,804
8/10/2023	Henry J. Fuchs	Insider	Sell	12,000	$90.43	$1,085,160.00	176,187
8/8/2023	George Eric Davis	EVP	Sell	11,000	$89.42	$983,620.00	69,474
8/7/2023	Jean Jacques Bienaime	CEO	Sell	4,000	$88.10	$352,400.00	428,732
5/10/2023	Jean Jacques Bienaime	CEO	Sell	30,000	$94.85	$2,845,500.00	426,213
4/10/2023	Jean Jacques Bienaime	CEO	Sell	10,000	$99.56	$995,600.00	425,896
4/6/2023	Jean Jacques Bienaime	CEO	Sell	10,000	$96.13	$961,300.00	425,896
4/3/2023	V. Bryan Lawlis	Director	Sell	8,500	$97.09	$825,265.00	28,950
3/13/2023	Jean Jacques Bienaime	CEO	Sell	8,000	$90.45	$723,600.00	487,856
3/10/2023	Jean Jacques Bienaime	CEO	Sell	15,000	$92.28	$1,384,200.00	487,856
2/13/2023	Jean Jacques Bienaime	CEO	Sell	6,000	$109.15	$654,900.00	320,324
2/10/2023	Jean Jacques Bienaime	CEO	Sell	15,000	$110.11	$1,651,650.00	320,324
1/25/2023	Jeffrey Robert Ajer	EVP	Sell	49,000	$115.70	$5,669,300.00	41,088
1/17/2023	Jean Jacques Bienaime	CEO	Sell	10,000	$111.55	$1,115,500.00	320,424
1/13/2023	Brian R. Mueller	CFO	Sell	2,500	$114.50	$286,250.00	27,746
1/13/2023	Jean Jacques Bienaime	CEO	Sell	10,000	$112.25	$1,122,500.00	320,424
12/13/2022	Brian R. Mueller	CFO	Sell	2,500	$107.50	$268,750.00	27,746
12/13/2022	Jean Jacques Bienaime	CEO	Sell	1,000	$106.89	$106,890.00	320,424
12/2/2022	Brian R. Mueller	CFO	Sell	7,001	$104.50	$731,604.50	27,746
12/2/2022	Jean Jacques Bienaime	CEO	Sell	1,500	$103.98	$155,970.00	321,424
11/23/2022	Brian R. Mueller	CFO	Sell	5,379	$98.73	$531,068.67	28,847
11/2/2022	Jeffrey Robert Ajer	EVP	Sell	3,000	$86.12	$258,360.00	41,088
10/31/2022	Jean Jacques Bienaime	CEO	Sell	1,500	$86.55	$129,825.00	322,824
10/31/2022	Mark J. Alles	Director	Buy	3,625	$86.75	$314,468.75	10,905
10/14/2022	Jean Jacques Bienaime	CEO	Sell	4,000	$89.89	$359,560.00	324,324
8/15/2022	Jean Jacques Bienaime	CEO	Sell	3,000	$95.21	$285,630.00	328,324
8/12/2022	Jean Jacques Bienaime	CEO	Sell	4,000	$94.75	$379,000.00	331,324
8/11/2022	Jeffrey Robert Ajer	EVP	Sell	3,000	$95.62	$286,860.00	44,088
8/8/2022	Charles Greg Guyer	EVP	Sell	6,205	$96.56	$599,154.80	42,168
7/8/2022	Brian R. Mueller	CFO	Sell	7,337	$89.50	$656,661.50	30,726
7/8/2022	George Eric Davis	EVP	Sell	7,398	$90.00	$665,820.00	58,941
5/26/2022	Jeffrey Robert Ajer	EVP	Sell	1,308	$78.94	$103,253.52	54,109
5/5/2022	Jean Jacques Bienaime	CEO	Sell	10,000	$84.14	$841,400.00	335,324
5/4/2022	Brian R. Mueller	CFO	Sell	11,800	$84.50	$997,100.00	38,639
5/2/2022	George Eric Davis	EVP	Sell	15,347	$80.38	$1,233,591.86	66,339
5/2/2022	Richard A. Meier	Director	Sell	3,878	$82.09	$318,345.02	104,014
4/28/2022	Jean Jacques Bienaime	CEO	Sell	20,000	$83.79	$1,675,800.00	334,983
4/18/2022	Jean Jacques Bienaime	CEO	Sell	20,000	$81.91	$1,638,200.00	334,983
4/14/2022	Jean Jacques Bienaime	CEO	Sell	10,000	$83.66	$836,600.00	334,983
4/14/2022	V. Bryan Lawlis	Director	Sell	4,250	$83.66	$355,555.00	23,970
4/13/2022	Jeffrey Robert Ajer	EVP	Sell	1,180	$82.47	$97,314.60	55,077
3/29/2022	Jeffrey Robert Ajer	EVP	Sell	1,618	$79.43	$128,517.74
3/23/2022	Jeffrey Robert Ajer	EVP	Sell	6,129	$81.78	$501,229.62
3/21/2022	George Eric Davis	EVP	Sell	6,129	$81.29	$498,226.41
3/10/2022	Jean Jacques Bienaime	CEO	Sell	15,000	$77.57	$1,163,550.00
2/28/2022	Dennis Slamon	Director	Sell	6,396	$78.33	$500,998.68
1/14/2022	V. Bryan Lawlis	Director	Sell	4,250	$87.61	$372,342.50
1/13/2022	Jean Jacques Bienaime	CEO	Sell	5,000	$87.86	$439,300.00
12/15/2021	Jean Jacques Bienaime	CEO	Sell	6,000	$82.71	$496,260.00
12/1/2021	Jean Jacques Bienaime	CEO	Sell	1,500	$87.22	$130,830.00

Urgent: This election is rigged

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.

SEC Filings (Institutional Ownership Changes) for BioMarin Pharmaceutical (NASDAQ:BMRN)

98.71% of BioMarin Pharmaceutical stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

BioMarin Pharmaceutical Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/20/2024	Virtu Financial LLC	11,504	$0.81M	0.0%	N/A	0.006%
11/18/2024	TD Private Client Wealth LLC	510	$36K	0.0%	+57.4%	0.000%
11/18/2024	Teachers Retirement System of The State of Kentucky	60,040	$4.22M	0.0%	-69.1%	0.032%
11/18/2024	Toronto Dominion Bank	23,942	$1.68M	0.0%	+31.3%	0.013%
11/18/2024	Neo Ivy Capital Management	21,020	$1.48M	0.5%	+2,225.2%	0.011%
11/16/2024	Geode Capital Management LLC	3,260,050	$228.63M	0.0%	+1.9%	1.711%
11/15/2024	Public Employees Retirement System of Ohio	69,113	$4.86M	0.0%	-9.0%	0.036%
11/15/2024	Nomura Asset Management Co. Ltd.	485,609	$34.13M	0.1%	+29.5%	0.255%
11/15/2024	Y Intercept Hong Kong Ltd	28,230	$1.98M	0.1%	N/A	0.015%
11/15/2024	MML Investors Services LLC	7,621	$0.54M	0.0%	+8.1%	0.004%
11/15/2024	XTX Topco Ltd	6,898	$0.49M	0.0%	+37.5%	0.004%
11/15/2024	Zacks Investment Management	17,802	$1.25M	0.0%	-17.5%	0.009%
11/15/2024	National Bank of Canada FI	919	$65K	0.0%	-93.6%	0.000%
11/15/2024	EP Wealth Advisors LLC	7,119	$0.50M	0.0%	N/A	0.004%
11/15/2024	United Services Automobile Association	12,343	$0.87M	0.0%	-16.7%	0.006%
11/15/2024	Kovitz Investment Group Partners LLC	5,081	$0.36M	0.0%	+63.9%	0.003%
11/15/2024	Worldquant Millennium Advisors LLC	63,572	$4.47M	0.0%	N/A	0.033%
11/15/2024	Wahed Invest LLC	4,584	$0.32M	0.1%	+11.4%	0.002%
11/15/2024	Two Sigma Advisers LP	181,314	$12.75M	0.0%	-21.8%	0.095%
11/15/2024	Stifel Financial Corp	30,537	$2.15M	0.0%	-30.6%	0.016%
11/15/2024	Quarry LP	2,500	$0.18M	0.0%	+1,853.1%	0.001%
11/15/2024	Readystate Asset Management LP	5,254	$0.37M	0.0%	-51.8%	0.003%
11/15/2024	Royal London Asset Management Ltd.	77,345	$5.44M	0.0%	+5.5%	0.041%
11/15/2024	Point72 DIFC Ltd	44,484	$3.13M	0.1%	N/A	0.023%
11/15/2024	Motley Fool Asset Management LLC	148,798	$10.43M	0.6%	-1.3%	0.078%
11/15/2024	Motley Fool Wealth Management LLC	424,597	$29.85M	1.5%	-4.7%	0.223%
11/15/2024	Investment Management Corp of Ontario	6,300	$0.44M	0.0%	+50.0%	0.003%
11/15/2024	Jacobs Levy Equity Management Inc.	52,071	$3.66M	0.0%	N/A	0.027%
11/15/2024	Holocene Advisors LP	563,476	$39.61M	0.2%	-21.0%	0.296%
11/15/2024	Centiva Capital LP	7,511	$0.53M	0.0%	N/A	0.004%
11/15/2024	Clearline Capital LP	319,772	$22.48M	1.0%	N/A	0.168%
11/15/2024	Arizona PSPRS Trust	24,100	$1.69M	0.1%	N/A	0.013%
11/15/2024	Paloma Partners Management Co	3,402	$0.24M	0.0%	N/A	0.002%
11/15/2024	Erste Asset Management GmbH	689,935	$48.53M	0.6%	N/A	0.362%
11/15/2024	True Wealth Design LLC	810	$57K	0.0%	+13,400.0%	0.000%
11/14/2024	Bellevue Group AG	330,976	$23.26M	0.4%	+533.7%	0.174%
11/14/2024	BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp	31,676	$2.23M	0.0%	-12.8%	0.017%
11/14/2024	Edgestream Partners L.P.	28,562	$2.01M	0.1%	N/A	0.015%
11/14/2024	PDT Partners LLC	33,028	$2.32M	0.2%	N/A	0.017%
11/14/2024	Fred Alger Management LLC	26,573	$1.87M	0.0%	-10.0%	0.014%
11/14/2024	Captrust Financial Advisors	10,900	$0.77M	0.0%	+34.1%	0.006%
11/14/2024	Vestal Point Capital LP	400,000	$28.12M	2.1%	N/A	0.210%
11/14/2024	Rockefeller Capital Management L.P.	266,633	$18.74M	0.1%	+16.5%	0.140%
11/14/2024	Martingale Asset Management L P	50,878	$3.58M	0.1%	-12.2%	0.027%
11/14/2024	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	880,453	$61.89M	0.0%	-13.1%	0.462%
11/14/2024	FORA Capital LLC	25,399	$1.79M	0.2%	+199.8%	0.013%
11/14/2024	MetLife Investment Management LLC	98,372	$6.92M	0.0%	-1.6%	0.052%
11/13/2024	Glenmede Trust Co. NA	3,614	$0.25M	0.0%	N/A	0.002%
11/13/2024	Bridgewater Associates LP	142,314	$10M	0.1%	+306.8%	0.075%
11/13/2024	Freedom Investment Management Inc.	4,838	$0.34M	0.0%	-6.7%	0.003%
11/13/2024	BNP Paribas Financial Markets	150,364	$10.57M	0.0%	-77.9%	0.079%
11/13/2024	Quantbot Technologies LP	2,427	$0.17M	0.0%	N/A	0.001%
11/13/2024	FMR LLC	206,538	$14.52M	0.0%	+21.7%	0.108%
11/13/2024	The Manufacturers Life Insurance Company	159,917	$11.24M	0.0%	-11.5%	0.084%
11/13/2024	Dynamic Technology Lab Private Ltd	14,376	$1.01M	0.1%	N/A	0.008%
11/13/2024	Daiwa Securities Group Inc.	18,006	$1.27M	0.0%	+7.0%	0.009%
11/12/2024	Alpha DNA Investment Management LLC	6,618	$0.47M	0.2%	N/A	0.003%
11/12/2024	Swedbank AB	388,529	$27.31M	0.0%	+34.7%	0.204%
11/12/2024	Charles Schwab Investment Management Inc.	1,401,628	$98.52M	0.0%	+4.1%	0.735%
11/9/2024	Primecap Management Co. CA	18,867,435	$1.33B	1.0%	+0.4%	9.900%
11/9/2024	Intech Investment Management LLC	53,856	$3.79M	0.0%	-7.2%	0.028%
11/8/2024	King Luther Capital Management Corp	28,840	$2.03M	0.0%	N/A	0.015%
11/8/2024	Grandfield & Dodd LLC	16,661	$1.17M	0.1%	+2.6%	0.009%
11/8/2024	EULAV Asset Management	131,000	$9.21M	0.2%	+12.9%	0.069%
11/8/2024	Advisors Asset Management Inc.	11,451	$0.81M	0.0%	+1.6%	0.006%
11/8/2024	Connor Clark & Lunn Investment Management Ltd.	116,257	$8.17M	0.0%	N/A	0.061%
11/8/2024	Howe & Rusling Inc.	49,652	$3.49M	0.3%	+101.2%	0.026%
11/8/2024	Commerce Bank	4,707	$0.33M	0.0%	-45.6%	0.002%
11/8/2024	B. Metzler seel. Sohn & Co. Holding AG	4,889	$0.34M	0.0%	N/A	0.003%
11/8/2024	Banque Cantonale Vaudoise	16,000	$1.13M	0.0%	-2.1%	0.008%
11/7/2024	Meeder Asset Management Inc.	735	$52K	0.0%	+920.8%	0.000%
11/7/2024	Quest Partners LLC	4,336	$0.31M	0.0%	N/A	0.002%
11/7/2024	Swiss National Bank	563,600	$39.62M	0.0%	+0.3%	0.296%
11/7/2024	AM Squared Ltd	1,400	$98K	0.2%	+75.0%	0.001%
11/6/2024	Mutual of America Capital Management LLC	102,894	$7.23M	0.1%	-5.4%	0.054%
11/6/2024	Comgest Global Investors S.A.S.	10,147	$0.71M	0.0%	-93.4%	0.005%
11/6/2024	Simplify Asset Management Inc.	8,489	$0.60M	0.0%	+67.5%	0.004%
11/6/2024	CIBC Asset Management Inc	6,731	$0.47M	0.0%	+5.6%	0.004%
11/6/2024	OneDigital Investment Advisors LLC	5,078	$0.36M	0.0%	-22.9%	0.003%
11/6/2024	Tokio Marine Asset Management Co. Ltd.	21,105	$1.48M	0.1%	+0.8%	0.011%
11/6/2024	Metis Global Partners LLC	5,450	$0.38M	0.0%	+9.7%	0.003%
11/5/2024	Rakuten Securities Inc.	1,260	$89K	0.0%	+125,900.0%	0.001%
11/5/2024	Sumitomo Mitsui Trust Group Inc.	456,097	$32.06M	0.0%	+4.7%	0.239%
11/5/2024	OVERSEA CHINESE BANKING Corp Ltd	3,498	$0.25M	0.0%	N/A	0.002%
11/5/2024	WCM Investment Management LLC	16,945	$1.20M	0.0%	+162.3%	0.009%
11/4/2024	Los Angeles Capital Management LLC	10,098	$0.71M	0.0%	N/A	0.005%
11/4/2024	Crossmark Global Holdings Inc.	13,322	$0.94M	0.0%	+20.6%	0.007%
11/2/2024	Covestor Ltd	1,030	$72K	0.0%	+336.4%	0.001%
11/1/2024	AIA Group Ltd	3,435	$0.24M	0.0%	+15.4%	0.002%
10/31/2024	Principal Financial Group Inc.	458,039	$32.20M	0.0%	-29.5%	0.241%
10/30/2024	Amalgamated Bank	90,666	$6.37M	0.1%	-5.5%	0.048%
10/30/2024	Stoneridge Investment Partners LLC	4,190	$0.30M	0.1%	N/A	0.002%
10/30/2024	AlphaCentric Advisors LLC	32,500	$2.28M	1.7%	+97.0%	0.017%
10/30/2024	Gulf International Bank UK Ltd	14,824	$1.04M	0.0%	-5.1%	0.008%
10/30/2024	Asset Management One Co. Ltd.	76,502	$5.38M	0.0%	-1.6%	0.040%
10/30/2024	National Pension Service	345,387	$24.28M	0.0%	+4.2%	0.182%
10/29/2024	Robeco Institutional Asset Management B.V.	210,666	$14.81M	0.0%	+157.4%	0.111%
10/29/2024	Van ECK Associates Corp	132,132	$9.25M	0.0%	-1.0%	0.070%
10/29/2024	Janney Montgomery Scott LLC	11,700	$0.82M	0.0%	+102.1%	0.006%
10/29/2024	Clear Creek Financial Management LLC	3,406	$0.24M	0.0%	N/A	0.002%

Data available starting January 2016

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Today's Range

Now: $64.26

$63.78

$64.46

50 Day Range

MA: $68.25

$61.93

$71.41

52 Week Range

Now: $64.26

$61.15

$99.56

Volume

1,304,400 shs

Average Volume

1,824,830 shs

Market Capitalization

$12.25 billion

P/E Ratio

38.48

Dividend Yield

N/A

Beta

0.31

Who are the company insiders with the largest holdings of BioMarin Pharmaceutical?: BioMarin Pharmaceutical's top insider shareholders include:
Jean Jacques Bienaime (Director)
Jean Jacques Bienaime (CEO)
Henry J Fuchs (Insider)
Jeffrey Robert Ajer (EVP)
Brian Mueller (CFO)
George Eric Davis (EVP)
Charles Greg Guyer (EVP)
V Bryan Lawlis (Director)
Erin Burkhart (CAO)
Learn More about top insider investors at BioMarin Pharmaceutical.
Who are the major institutional investors of BioMarin Pharmaceutical?: BioMarin Pharmaceutical's top institutional investors include:
Primecap Management Co. CA — 9.90%
Geode Capital Management LLC — 1.71%
Charles Schwab Investment Management Inc. — 0.74%
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC — 0.46%
Erste Asset Management GmbH — 0.36%
Swiss National Bank — 0.30%
Learn More about top institutional investors of BioMarin Pharmaceutical stock.
Which major investors are selling BioMarin Pharmaceutical stock?: During the previous quarter, BMRN stock was sold by these institutional investors:
BNP Paribas Financial Markets
Jane Street Group LLC
Assenagon Asset Management S.A.
Principal Financial Group Inc.
Holocene Advisors LP
Comgest Global Investors S.A.S.
Teachers Retirement System of The State of Kentucky
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
During the previous year, company insiders that have sold BioMarin Pharmaceutical company stock include:
Jean Jacques Bienaime (Director)
Jean Jacques Bienaime (CEO)
Henry J Fuchs (Insider)
Jeffrey Robert Ajer (EVP)
Brian Mueller (CFO)
George Eric Davis (EVP)
Charles Greg Guyer (EVP)
Learn More investors selling BioMarin Pharmaceutical stock.
Which major investors are buying BioMarin Pharmaceutical stock?: During the last quarter, BMRN stock was bought by institutional investors including:
Erste Asset Management GmbH
Vestal Point Capital LP
Clearline Capital LP
Bellevue Group AG
Robeco Institutional Asset Management B.V.
Connor Clark & Lunn Investment Management Ltd.
Nomura Asset Management Co. Ltd.
LMR Partners LLP